Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation

Background:Chromogenic anti-factor Xa activity (AXA) assay is reported to be the most appropriate method to measure the pharmacodynamics of apixaban, but the distribution of AXA in non-valvular atrial fibrillation (NVAF) patients on apixaban therapy has not been fully elucidated.Methods and Results:...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation Journal 2015/11/25, Vol.79(12), pp.2584-2590
Hauptverfasser:	Osanai, Hiroyuki, Ajioka, Masayoshi, Masutomi, Tomohiro, Kuwayama, Tasuku, Ishihama, Sota, Sakamato, Yusuke, Otaka, Naoya, Sakaguchi, Teruhiro, Inoue, Yosuke, Kanbara, Takahiro, Nakashima, Yoshihito, Asano, Hiroshi, Sakai, Kazuyoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Factors Aged Aged, 80 and over Anti-factor Xa activity Apixaban Atrial fibrillation Atrial Fibrillation - blood Atrial Fibrillation - drug therapy Dose-Response Relationship, Drug Factor Xa Inhibitors - blood Female Humans Male Pyrazoles - administration & dosage Pyrazoles - pharmacokinetics Pyridones - administration & dosage Pyridones - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background:Chromogenic anti-factor Xa activity (AXA) assay is reported to be the most appropriate method to measure the pharmacodynamics of apixaban, but the distribution of AXA in non-valvular atrial fibrillation (NVAF) patients on apixaban therapy has not been fully elucidated.Methods and Results:Steady-state trough and peak AXA were measured in 124 NVAF patients taking apixaban. In 25 patients, baseline, first peak, and trough AXA were also examined, and were 0.01±0.02 IU/ml, 0.83±0.43 IU/ml, and 0.34±0.17 IU/ml, respectively. First trough AXA was significantly lower than steady-state trough AXA, although it was significantly higher than baseline (P
ISSN:	1346-9843 1347-4820
DOI:	10.1253/circj.CJ-15-0470